secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-064439
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q1 2025 revenue $40.8M (-10% YoY); net loss $26.0M, adj EBITDA loss $16.9M
--------------------------------------------------------------------------------

- First-quarter revenue $40.8M, down 10% YoY; consumables -16%, instruments +24%, services -16%.
- Net loss $26.0M improved 19% YoY ($32.2M); adjusted EBITDA loss $16.9M improved 29%.
- Non-GAAP gross margin 53.2%, down from 56.2% in Q1 2024 due to volume, mix, and pricing.
- Cash & equivalents $260.7M, no material debt; FY2025 revenue outlook reaffirmed at $165-175M.
- Operating expenses fell 38% YoY to $52.7M, driven by merger cost synergies and SBS productivity gains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000095017025064439/0000950170-25-064439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000095017025064439/lab-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer